BioSpace News Archive

StageZero Life Sciences, Ltd. announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe.

Evogene Ltd. today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2021 and provided a business update.

Arcturus Therapeutics Holdings Inc. announced that Company management will participate in a Fireside Chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 1:35 p.m. ET.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis.

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura™) for the treatment of vitiligo.

Cortexyme, Inc. announced that the company will participate at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases, which is a hybrid event taking place March 15-20, 2022 in Barcelona, Spain, as well as virtually.

SIWA Therapeutics, Inc. (“SIWA”), a Chicago-based biopharmaceutical company announced today that SIWA’s proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer.

Biomea Fusion, Inc. (Nasdaq: BMEA), today announced that an abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions.

BiondVax Pharmaceuticals Ltd. announced that it had been negotiating with the European Investment Bank terms of restructuring of its outstanding €24 million loan.